Wave Life Sciences
Develops PRISM-based RNA medicines across editing, silencing, splicing, and RNAi.
$5.09
After-hours close+0.05 (+1.07%)
At close$5.04(−2.33%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 93.42%Insiders 14.41%
Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.
Shares outstanding 197.05M · Float 162.27M · 82.4% free float
Institutions13F, as of Jun 30, 2026
250 holders · 184.07M shares · 51 new positions · 150 increased · 55 reduced · 46 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 26.98M | 13.69% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 19.20M | 9.75% | +5.09M | Aug 7, 2026 |
| GSK PLC | 18.25M | 9.26% | 0 | Aug 13, 2026 |
| Maverick Capital Ltd | 10.28M | 5.22% | +116.7K | Aug 14, 2026 |
| Driehaus Capital Management LLC | 5.44M | 2.76% | +12.1K | Aug 14, 2026 |
| Primecap Management Co/CA/ | 5.35M | 2.72% | +521.7K | Aug 14, 2026 |
| 683 Capital Management, LLC | 4.95M | 2.51% | +50.0K | Aug 14, 2026 |
| FMR LLC | 4.92M | 2.50% | −270.3K | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Rajeev Shahincl. RA Capital Healthcare Fund, L.P., Peter Kolchinsky +1 more | 16.80% | 34.31M | 13D | Aug 11, 2026 ↗ |
| BlackRock, Inc. | 6.10% | 9.36M | 13G | Feb 5, 2025 ↗ |
| Maverick Capital, Ltd. | 5.40% | 8.26M | 13G | Feb 14, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | director, 10 percent owner: | 26.98M | 13.69% | Mar 30, 2026 |
| GSK plc | 10 percent owner | 18.25M | 9.26% | Dec 15, 2025 |
| Chandra Vargeese | officer: See Remarks | 408.2K | 0.21% | Feb 11, 2026 |
| Paul Bolno | director, officer: President and CEO | 275.5K | 0.14% | Feb 11, 2026 |
| Gregory L. Verdine | director | 275.2K | 0.14% | Dec 10, 2025 |
| Kyle Moran | officer: Chief Financial Officer | 134.4K | 0.07% | Feb 11, 2026 |
| Erik Ingelsson | officer: Chief Scientific Officer | 87.9K | 0.04% | Apr 17, 2026 |
| Chris Francis | officer: See Remarks | 61.9K | 0.03% | Feb 27, 2026 |
| Christopher I. Wright | officer: Chief Medical Officer | 45.6K | 0.02% | Apr 17, 2026 |
| Heidi L. Wagner | director | 44.9K | 0.02% | Aug 13, 2026 |
1 ten-percent owner holds 18.25M shares by Form 4, outside the officers-and-directors figure above · 7 people have not refiled in the last 18 months (3.06M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 11, 2026 | Heidi L. Wagnerdirector | Sale | 7,000 | $6.01 | 44,930 |
| Aug 11, 2026 | Aik Na Tandirector | Sale | 432 | $6.01 | 24,968 |
| Aug 11, 2026 | Ken Takanashidirector | Sale | 3,864 | $6.01 | 20,079 |
| Aug 12, 2026 | Adrian Rawcliffedirector | Sale | 12,700 | $5.29 | 0 |
| Mar 26, 2026 | Ra Capital Management, L.P.director, 10 percent owner: | Purchase · 2 lots | 5,305,782 | $6.08 | 23,508,791 |
| Mar 27, 2026 | Ra Capital Management, L.P.director, 10 percent owner: | Purchase | 2,495,623 | $6.43 | 26,004,414 |
| Mar 30, 2026 | Ra Capital Management, L.P.director, 10 percent owner: | Purchase | 971,091 | $6.50 | 26,975,505 |
| Feb 26, 2026 | Chris Francisofficer: See Remarks | Sale · 2 lots | 33,194 | $15.05 | 61,867 |
| Feb 9, 2026 | Chandra Vargeeseofficer: See Remarks | Sale | 3,228 | $13.45 | 408,246 |
| Feb 9, 2026 | Chris Francisofficer: See Remarks | Sale | 1,883 | $13.45 | 61,867 |
CongressHouse and Senate disclosures
Not reported.